Psychedelic Science 2025, a leading conference on psychedelic research, policy, and thought leadership, announces its initial lineup of speakers, including former U.S. Senator Kyrsten Sinema, former Ohio Representative Tim Ryan, and other prominent researchers, policymakers, and advocates.

The 5-HT2 agonist pipeline is robust, with over 20 pharmaceutical companies actively developing 22+ pipeline drugs. Advancements in precision medicine and personalized approaches are driving the market, enabling selective targeting of receptor subtypes and improving safety and efficacy.

Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc., a leader in novel neuropsychiatry therapeutics. Cybin's primary focus is on two lead pipeline candidates, CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, which have shown promising results in clinical trials.

Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.